Utilization of nanotechnology to enhance percutaneous absorption of acyclovir in the treatment of herpes simplex viral infections

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 3973-3985

  Al Subaie, Mutlaq M ^a   Hosny, Khaled M ^a,b   El Say, Khalid Mohamed ^a,c   Ahmed, Tarek A ^a,c   Aljaeid, Bader M ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b Beni Suef University   (Egypt)

^c Al Azhar University   (Egypt)

Author keywords

Acyclovir; Experimental design; Hydrogel; Nanoemulsion; Optimization; Relative bioavailability

Indexed keywords

ACICLOVIR; CHITOSAN; EUGENOL; HYDROGEL; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG MIXTURE; DRUG SOLUBILITY; EX VIVO STUDY; HERPES SIMPLEX; HYDROGEL; MALE; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; NANOEMULSION; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PREDICTION; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; RAT; RESPONSE SURFACE METHOD; STATISTICAL ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG EFFECTS; METABOLISM; SKIN; SKIN ABSORPTION; THEORETICAL MODEL; WISTAR RAT;

RATTUS; SYZYGIUM AROMATICUM;

ACYCLOVIR; ANIMALS; BIOLOGICAL AVAILABILITY; CHITOSAN; EUGENOL; HERPES SIMPLEX; HYDROGELS; MALE; MODELS, THEORETICAL; MOLECULAR WEIGHT; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; RATS; RATS, WISTAR; SKIN; SKIN ABSORPTION;

EID: 84933545213     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S83962     Document Type: Article

References (34)

1. World Health Organization. WHO Model List of Essential Medicines 18th List; 2013. Available from: http://www.who.int/medicines/publications/essentialmedicines/en/index.html. Accessed May 9, 2015.
2. Wilhelmus KR, Beck RW, Moke PS, et al. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med. 1998;339: 300–306.
3. Uchoa UB, Rezende RA, Carrasco MA, Rapuano CJ, Laibson PR, Cohen EJ. Long-term acyclovir use to prevent recurrent ocular herpes simplex virus infection. Arch Ophthalmol. 2003;121:1702–1704.
4. Kristl A, Srcic S, Vrecer F, Sustar B, Vojnovic D. Polymorphism and pseudopolymorphism: infuencing the dissolution properties of the guanine derivative acyclovir. Int J Pharm. 1996;139:231–235.
5. von Plessing Rossel C, Carreño JS, Rodríguez-Baeza M, Alderete JB. Inclusion complex of the antiviral drug acyclovir with cyclodextrin in aqueous solution and in solid phase. Quim Nova. 2000;23:749–752.
6. De Clercq E. Antivirals for the treatment of herpesvirus infections. J Antimicrob Chemother. 1993;32 Suppl A:121–132.
7. Shah P, Bhalodia D, Shelat P. NE: a pharmaceutical review. Syst Rev Pharm. 2010;1(1):24.
8. Anton N, Benoit J-P, Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates – a review. J Control Release. 2008;12:185–199.
9. Forster T. Principles of emulsion formation. In: Rieger MM, Rhein LD, editors. Surfactants in Cosmetics. 2nd ed. New York, NY, USA: Marcel Dekker Inc; 1997.
10. Ahmed OA, Badr-Eldin SM, Tawfk MK, Ahmed TA, El-Say KM, Badr JM. Design and optimization of self-nanoemulsifying delivery system to enhance quercetin hepatoprotective activity in paracetamol-induced hepatotoxicity. J Pharm Sci. 2014;103:602–612.
11. El-Say KM, Ahmed TA, Badr-Eldin SM, Fahmy U, Aldawsari H, Ahmed OA. Enhanced permeation parameters of optimized nanostruc-tured simvastatin transdermal flms: ex vivo and in vivo evaluation. Pharm Dev Technol. July 14, 2014. [Epub ahead of print].
12. Gutiérrez JM, González C, Maestro A, Solè I, Pey CM, Nolla J. Nano-emulsions: new applications and optimization of their preparation. Curr Opin Colloid Interface Sci. 2008;13:245–251.
13. Jadhav K, Shaikh I, Ambade K, Kadam V. Applications of microemul-sion based drug delivery system. Curr Drug Deliv. 2006;3:267–273.
14. Reddy RB, Kumari CTL, Sowjanya GN, Sindhuri S, Bandhav P. NEs an emerging trend: a review. Int J Pharm Res Dev. 2011;4:137–152.
15. Peppas NA, Mikos AG. Preparation methods and structure of hydrogels. In: Peppas NA, editor. Hydrogels in Medicine and Pharmacy. Boca Raton, FL, USA: CRC Press; 1986.
16. Bell CL, Peppas NA. Biomedical membranes from hydrogels and interpolymer complexes. In: Advances in Polymer Science. Volume 122. Berlin, Germany: Springer-Verlag; 1995.
17. Ryu J-M, Chung S-J, Lee M-H, Kim C-K. Increased bioavailability of propranolol in rats by retaining thermally gelling liquid suppositories in the rectum. J Control Release. 1999;59:163–172.
18. Sinha VR, Khosla L. Bioabsorbable polymers for implantable therapeutic systems. Drug Dev Ind Pharm. 1998;24:1129–1138.
19. Cohen S, Lobel E, Trevgoda A, Peled Y. A novel in situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye. J Control Release. 1997;44:201–208.
20. Patel VR, Amiji MM. Preparation and characterization of freeze-dried chitosan-poly(ethylene oxide) hydrogels for site-specifc antibiotic delivery in the stomach. Pharm Res. 1996;13:588–593.
21. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000;45:89–121.
22. Bachhav YG, Patravale VB. Microemulsion based vaginal gel of fucon-azole: formulation, in vitro and in vivo evaluation. Int J Pharm. 2009; 365:175–179.
23. Al-Suwayeh SA, Taha EI, Al-Qahtani FM, Ahmed MO, Badran MM. Evaluation of skin permeation and analgesic activity effects of carbopol lornoxicam topical gels containing penetration enhancer. Scientifc World Journal. 2014;2014:127495.
24. Shibata N, Kitamura A, Yoshikawa Y, Inoue T, Bamba T, Takada K. Simultaneous determination of aciclovir and ganciclovir in plasma by HPLC and pharmacokinetic interactions. Pharm Pharmacol Commun. 2000;6:501–506.
25. Chaudhary B, Verma S. Preparation and evaluation of novel in situ gels containing acyclovir for the treatment of oral herpes simplex virus infections. Scientifc World Journal. 2014;2014:280928.
26. Council for International Organization of Medical Sciences. International guiding principles for biomedical research involving animals, 2012. Available from: http://grants.nih.gov/grants/olaw/Guiding_Principles_2012.pdf. Accessed May 10, 2015.
27. European Parliament. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientifc purposes. Available from: http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm. Accessed May 10, 2015.
28. Padullés A, Colom H, Armendariz Y, et al. Determination of ganciclovir in human plasma by ultra performance liquid chromatography-UV detection. Clin Biochem. 2012;45:309–314.
29. Şenyiğit ZA, Karavana SY, Eraç B, Gürsel Ö, Limoncu MH, Baloğlu E. Evaluation of chitosan based vaginal bioadhesive gel formulations for antifungal drugs. Acta Pharm. 2014;64:139–156.
30. Williams AC, Barry B W. Penetration enhancers. Adv Drug Deliv Rev. 2004;56:603–618.
31. Mutalik S, Udupa N. Effect of some penetration enhancers on the permeation of glibenclamide and glipizide through mouse skin. Pharmazie. 2003;58:891–894.
32. Thacharodi D, Rao KP. Transdermal absorption of nifedipine from microemulsions of lipophilic skin penetration enhancers. Int J Pharm. 1994;111:235–240.
33. Baboota S, Shakeel F, Ahuja A, Ali J, Shafq S. Design, development and evaluation of novel NE formulations for transdermal potential of celecoxib. Acta Pharm. 2007;57:315–332.
34. Huang C-T, Tsai M-J, Lin Y-H, et al. Effect of microemulsions on transdermal delivery of citalopram: optimization studies using mixture design and response surface methodology. Int J Nanomedicine. 2013;8: 2295–2304.